New Alzheimer´s drug hailed as ‘beginning of the end’ in search for treatment

Phase three clinical trials have shown that lecanemab, made by Tokyo-based Eisai, can halt the declines in memory and thinking among patients in the earliest stages.Phase three clinical trials have shown that lecanemab, made by Tokyo-based Eisai, can halt the declines in memory and thinking among patients in the earliest stages.Read MoreHealth News | Mail Online